# Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals

> **NCT01712425** · PHASE1 · COMPLETED · sponsor: **IrsiCaixa** · enrollment: 48 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** 0-24 week prime/boost regimen
- **BIOLOGICAL:** 0-8 week prime/boost regimen

## Key facts

- **NCT ID:** NCT01712425
- **Lead sponsor:** IrsiCaixa
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712425, "Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01712425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*